Navigation Links
Decision by Medicare's CMS to Deny Coverage for 'Virtual' Colon Cancer Tests Underscores Lack of Evidence on Cancer Prevention
Date:5/13/2009

BETHESDA, Md., May 13 /PRNewswire-USNewswire/ -- The decision by the Centers for Medicare & Medicaid Services to deny payment for CT colonography, also known as "virtual" colonoscopy, a radiographic examination of the abdomen, underscores the lack of sufficient evidence on the test's potential as an appropriate option for the screening and prevention of colorectal cancer.

"One of the primary issues identified by CMS is that patients who have polyps identified by CT scan of the abdomen will still have to undergo complete colonoscopy," explained Eamonn Quigley, M.D., FACG, President of the American College of Gastroenterology. The American College of Gastroenterology and the Multi-Society Task Force Guideline on Colorectal Cancer in recent guidelines have stated clear preferences for tests which prevent colorectal cancer.

The American College of Gastroenterology has long supported the lifesaving potential of screening by colonoscopy specifically because it is widely available, safe and effective. "There is no evidence that any radiographic test, including CT colonography, prevents the development of colorectal cancer. Colonoscopy is one of the most powerful preventive tools in clinical medicine because of its excellent sensitivity in detecting polyps and its potential for removing them and breaking the sequence of polyp to cancer in a single diagnostic and therapeutic intervention," said Dr. Quigley.

Physician experts from the American College of Gastroenterology believe consumers should recognize that CT colonography does not currently represent a painless or risk-free procedure, nor does it eliminate the need for bowel cleansing which many patients report as a barrier to screening. There is also evidence that due to the insertion of a tube in the rectum and insufflation of the abdomen with air or gas, the patients, who are not sedated and awake, tend to feel discomfort.

The College recognizes that CT colonography might be an option to consider for patients who, because of infirmity or the presence of significant co-morbid diseases, would be at an increased risk for complications in relation to colonoscopy. However, the vast majority of patients would benefit from the potentially lifesaving benefits of screening for colon cancer using colonoscopy.

When evaluating new potential screening technologies, including CT colonography, the ACG has focused its evaluation on several pieces of evidence including: sensitivity for identification of polyps of various sizes, standards for polyp removal, balancing patient risks (in this case from radiation exposure) with benefits, frequency of exams and the economic impact to the healthcare system of separate diagnostic and therapeutic exams.

"There is a tremendous body of evidence that shows that clearing the colon of polyps, including small polyps, significantly reduces colorectal cancer mortality. Because of its excellent sensitivity in detecting polyps and its potential for removing them and breaking the sequence of polyp to cancer in a single diagnostic and therapeutic intervention, complete colonoscopy is one of the most powerful preventive tools in clinical medicine. Until a radiographic test can meet that standard, gastroenterologists will continue to champion the lifesaving potential of colonoscopy," added Dr. Quigley.


'/>"/>
SOURCE American College of Gastroenterology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Spectranetics to Appeal Decision in Patent Litigation
4. Canadas government funds $1.6M in modern geography to support public health decisions
5. Parents participation in medical decisions linked to self-efficacy
6. Decision-making by residents on-call has miniscule negative impact on patient care
7. Political decisions harming cancer treatment in Europe
8. UniCare Introduces Consumer-Driven Health Products to Give Consumers a Bigger Role in Health Care Decisions
9. Equipping your Sales Force to Influence Hospital Formulary Decision-Makers
10. Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System
11. Autism Speaks Applauds Supreme Court Decision Upholding Families Right to Challenge IEPs Without First Trying Out School District Proposed Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: